Skip to main content
Vance Fowler, MD, Infectious Disease, Durham, NC, Duke University Hospital

VanceFowlerMDMHS

Infectious Disease Durham, NC

Professor, Medicine, Duke University School of Medicine

Dr. Fowler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Fowler's full profile

Already have an account?

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Infectious Disease, 1996 - 1999
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 1993 - 1996
  • University of North Carolina at Chapel Hill School of Medicine
    University of North Carolina at Chapel Hill School of MedicineClass of 1993

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 1995 - 2024
  • American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Elected Member The American Society for Clinical Investigation, 2007
  • Association of American Physicians
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcu...  
    Helen W Boucher, Sara E Cosgrove, G Ralph Corey, Thomas L Holland, Vance G Fowler, Clinical Infectious Diseases

Other

Press Mentions

  • The Free Market Is Failing Us on Antibiotics
    The Free Market Is Failing Us on AntibioticsDecember 25th, 2022
  • DARPA ECHO Program Testing Epigenome or DNA Changes for Tracking Exposure to Threat Agents, Weapons of Mass Destruction (WMD) on Battlefield
    DARPA ECHO Program Testing Epigenome or DNA Changes for Tracking Exposure to Threat Agents, Weapons of Mass Destruction (WMD) on BattlefieldSeptember 30th, 2021
  • Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
    Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical InvestigationJune 17th, 2020
  • Join now to see all

Hospital Affiliations